Skip to content
  • menu secondaire

    • Investors
    • Careers
    • Terms of Use
    • privacy policy
    • Cookie policy
    • Contacts
    • Profile
      • About Transgene
      • Management Team
      • Board of Directors
      • Corporate governance
      • Ethics & compliance
      • Collaborations
      • Partners
    • Technology
      • Viral-based Immunotherapies
        • Therapeutic Vaccines
        • Oncolytic Viruses
      • myvac Platform
      • Invir.IO Platform
      • Publications and Presentations
    • Portfolio
      • Pipeline
      • TG4050
      • TG4001
      • TG6002
      • TG6050
      • BT-001
      • Clinical trials FAQ
    • Press Releases
    • French

    Category: Myvac

    Phase 1 studies of personalized neoantigen vaccine TG4050 in ovarian carcinoma (OC) and head and heck carcinoma (HNSCC)

    JP Delord, et al. ASCO 2022 Abstract available on the ASCO website – Download the poster here Poster Presentation

    Published 6 June 2022
    Categorized as 2022, Myvac, Publication, TG4050

    Transgene Presented Additional Phase I Data with TG4050 (myvac® platform) at ASCO 2022

    Transgene presented additional Phase I Data with TG4050 at ASCO 2022

    Published 6 June 2022
    Categorized as 2022, 2022, Press release, Invir.IO, Myvac, Press release, TG4050

    Transgene to Present Updated Positive Preliminary Data from the Phase I Clinical Trials with TG4050 (myvac® platform) at ASCO 2022

    Transgene to present updated positive preliminary data at ASCO 2022

    Published 27 May 2022
    Categorized as 2022, 2022, Press release, Invir.IO, Myvac, Press release, TG4050

    Phase I trials of personalized cancer vaccine TG4050 in surgically treated high-risk head and neck squamous cell carcinoma (HNSCC) and relapsing ovarian cancer (OvC) patients

    MS Block et al. AACR 2022 Download the publication here

    Published 12 April 2022
    Categorized as 2022, Myvac, publication HP en, TG4050

    Phase I trials of personalized cancer vaccine TG4050 in surgically treated high-risk head and neck squamous cell carcinoma (HNSCC) and relapsing ovarian cancer (OvC) patients

    MS Block et al.AACR 2022Read the abstract here – Download the poster herePoster Presentation

    Published 8 April 2022
    Categorized as 2022, Myvac, Publication, TG4050

    Transgene to Present New Positive Preliminary Phase I Clinical Data at AACR 2022, Reinforcing the Potential of TG4050

    Transgene to present new positive preliminary Phase I Clinical data

    Published 8 April 2022
    Categorized as 2022, 2022, Press release, Invir.IO, Myvac, Press release, TG4050

    Transgene to Present New Positive Preliminary Phase I Data on TG4050 (myvac® platform), its Individualized Therapeutic Cancer Vaccine, at AACR 2022

    Transgene to present new positive preliminary Phase I data on TG4050

    Published 9 March 2022
    Categorized as 2022, 2022, Press release, Invir.IO, Myvac, Press release, TG4050

    First Head & Neck Cancer Patient Enrolled in the UK in a Phase I Trial with TG4050 (myvac® Platform), Transgene’s Innovative Individualized Immunotherapy

    First Head & Neck Cancer Patient Enrolled in the UK in a Phase I Trial with TG4050 (myvac® Platform), Transgene’s Innovative Individualized Immunotherapy

    Published 28 June 2021
    Categorized as 2021, dates, Myvac, Press release, TG4050

    Transgene to Present its Immuno-Oncology Expertise at Upcoming Scientific Conferences

    20210302 – Transgene Scientific Conferences

    Published 2 March 2021
    Categorized as 2021, Invir.IO, Myvac, Press release

    First Head & Neck Cancer Patient Treated in France in a Phase I trial with TG4050 (myvac® Platform), Transgene’s Innovative Individualized Immunotherapy

    20210121 TG4050 1st patient HNSCC EN

    Published 21 January 2021
    Categorized as 2021, Myvac, Press release, TG4050

    Posts navigation

    Page 1 … Page 3 Older posts
    • Investors
    • Careers
    • Terms of Use
    • privacy policy
    • Cookie policy
    • Contacts

    Transgene sa
    400 Boulevard Gonthier d’Andernach - Parc d'Innovation - CS80166
    67405 Illkirch Graffenstaden Cedex - France |
    Tel. : + 33 (0) 3 88 27 91 00

     

    © 2021 Transgene - All rights reserved
    Credits

    This Website uses cookies to provide you with the most relevant experience. By clicking on the "Accept All" button, you agree to the deposit of all cookies on your terminal. You can change your preferences or withdraw your consent at any time by clicking on the "Settings" button.
    More informationSettings Decline all ACCEPT ALL
    Cookies

    Privacy Overview

    This website uses cookies to improve your experience while you browse the website. Of these, cookies categorized as necessary are stored on your browser as they are essential for the functioning of basic functionalities of the website. We also use third-party cookies which advise us to analyze and understand how you use this website. These cookies will only be stored in your browser with your consent. You also have the option of deactivating these cookies. But disabling some of these cookies may affect your browsing experience.
    Necessary
    Always Enabled
    Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously. Analytical cookies used to understand how visitors interact with the website.
    Functional (video)
    Functional cookies help to perform certain functions such as sharing website content on social media platforms, collecting feedback and other third-party functionality.
    Third-party application cookies (twitter)
    Cookies déposés par des sociétés autres que Transgene. Ces cookies sont susceptibles de transmettre aux sociétés tiers des informations en lien avec les pages consultées. Ces sociétés doivent s’engager à garder ces données confidentielles dans le cadre de la loi informatique et libertés (6 janvier 1978).
    Save & Accept
    Powered by CookieYes Logo